Citizens Jmp Cuts KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $28.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lowered by Citizens Jmp from $29.00 to $28.00 in a report published on Thursday,Benzinga reports. The firm currently has a market outperform rating on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on KALV. Needham & Company LLC boosted their price target on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, HC Wainwright raised their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ:KALV opened at $19.33 on Thursday. The firm has a 50 day simple moving average of $16.04 and a 200-day simple moving average of $14.46. KalVista Pharmaceuticals has a twelve month low of $9.23 and a twelve month high of $19.95. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company has a market capitalization of $990.08 million, a PE ratio of -4.89 and a beta of -0.35.

Insider Activity at KalVista Pharmaceuticals

In other news, insider Nicole Sweeny sold 3,975 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the sale, the insider owned 47,003 shares in the company, valued at approximately $731,836.71. This represents a 7.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total value of $2,960,232.75. Following the transaction, the insider directly owned 5,129,340 shares in the company, valued at approximately $86,942,313. This represents a 3.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 248,009 shares of company stock worth $4,213,467 in the last three months. Company insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at approximately $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,939 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of KalVista Pharmaceuticals by 3.7% during the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after purchasing an additional 12,263 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of KalVista Pharmaceuticals by 2.8% during the second quarter. Geode Capital Management LLC now owns 941,212 shares of the specialty pharmaceutical company’s stock worth $10,642,000 after purchasing an additional 25,971 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of KalVista Pharmaceuticals by 26.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock worth $110,000 after purchasing an additional 2,061 shares during the period.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.